Tazac Pulvule is a medicine containing the active ingredient(s) nizatidine. On this page you will find out more about Tazac Pulvule, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: nizatidine
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Tazac Pulvule 150 mg hard capsule, 60
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
TAZAC is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. TAZAC is also indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of active duodenal ulcer. Continuous therapy with nizatidine for longer than 1 year has not been studied. TAZAC is indicated for up to 8 weeks for the treatment of benign gastric ulcer. TAZAC is indicated for up to 12 weeks for the treatment of oesophagitis, including erosive and ulcerative oesophagitis and associated heartburn due to reflux.
Table of characteristics
Size 2 capsule consisting of dark yellow cap and a pale yellow body, printed with "N150" on body.
Images are the copyright of the Pharmacy Guild of Australia
|Dosage Form||Capsule, hard|
|Route of administration||Oral|
10: Prescription Only Medicine, or Prescription Animal Remedy
100: Prescription Only Medicine, or Prescription Animal Remedy
14: Prescription Only Medicine, or Prescription Animal Remedy
2 capsules (starter pack): Prescription Only Medicine, or Prescription Animal Remedy
60: Prescription Only Medicine, or Prescription Animal Remedy
8 capsules starter pack: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||No information available|
|Life time||3 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 February 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.